Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Receives Consensus Recommendation of “Hold” from Analysts

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has received a consensus recommendation of “Hold” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $14.00.

A number of brokerages recently weighed in on ATRA. StockNews.com assumed coverage on Atara Biotherapeutics in a report on Wednesday, June 26th. They set a “hold” rating on the stock. The Goldman Sachs Group lowered their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating on the stock in a research note on Wednesday, July 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a $13.00 price objective on shares of Atara Biotherapeutics in a research note on Tuesday, August 13th. Mizuho upgraded shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and lowered their target price for the stock from $25.00 to $18.00 in a research report on Friday, August 16th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st.

Atara Biotherapeutics Stock Performance

Shares of Atara Biotherapeutics stock opened at $8.08 on Friday. The company has a market capitalization of $38.90 million, a P/E ratio of -0.15 and a beta of 0.50. Atara Biotherapeutics has a 1 year low of $4.96 and a 1 year high of $45.75. The company’s fifty day moving average is $8.26 and its two-hundred day moving average is $12.21.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The business had revenue of $28.64 million during the quarter, compared to the consensus estimate of $48.30 million. As a group, equities analysts expect that Atara Biotherapeutics will post -12.09 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Hedge funds have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics during the second quarter worth approximately $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter worth $53,000. Redmile Group LLC boosted its holdings in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Atara Biotherapeutics by 8,916.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after acquiring an additional 4,903,159 shares during the period. Finally, Delap Wealth Advisory LLC acquired a new stake in Atara Biotherapeutics during the first quarter worth about $29,000. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.